Intrexon Corporation (NYSE:XON): According to 8 Analysts, The short term target price has been estimated at $ 48.13.The target price could deviate by a maximum of $12.68 from the forecast price. In the near term, the target price could hit a high of $65 and a low of $ 29.
Many analysts have stated their opinion on the company shares. JMP Securities initiates coverage on Intrexon Corporation (NYSE:XON) The current rating of the shares is Market Outperform. The rating by the firm was issued on May 3, 2016. For the current week, the company shares have a recommendation consensus of Buy.
On the companys insider trading activities, Kirk Randal J, CEO of Intrexon Corp, had purchased 124,475 shares on December 11, 2015. The total value of the transaction was $3,714,334. The information was disclosed with the SEC in a Form 4 Filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Intrexon Corporation (NYSE:XON) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.14 points or 0.55% at $25.13 with 1,444,340 shares getting traded. Post opening the session at $25, the shares hit an intraday low of $25 and an intraday high of $26.7 and the price was in this range throughout the day. The company has a market cap of $2,969 million and the number of outstanding shares have been calculated to be 118,164,614 shares. The 52-week high of Intrexon Corporation (NYSE:XON) is $69.45 and the 52-week low is $18.5201.
Intrexon Corporation is engaged in the field of synthetic biology. The Company designs, builds and regulates gene programs, which are Deoxyribonucleic Acid (DNA) sequences that consist of genetic components. The Companys synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells. The Companys technologies include UltraVector, RheoSwitch Therapeutic System, Cell Systems Informatics, Protein Engineering, AttSite Recombinases, LEAP (Laser Enabled Analysis and Processing), Antibody Discovery, Neurospora & Agaricus Platforms, Endometrial Regenerative Cells, ActoBiotics, Porcine Research Models and BeyondBio. The Company serves various markets, including health, food, energy, environment and consumer. The Company has five operating divisions: Human Therapeutics, Synthetic Immunology, Animal Sciences, Agricultural Biotech, and Industrial Products.